C.R. Bard, a New Jersey medical devicemaker, announced its acquisition of SenoRX, an Irvine, Calif., a breast cancer medical devicemaker, for $200 million, or $11 per share, the company said in a news release.
Bard acquires Calif. devicemaker
SenoRX shareholders voted to approve the previously announced acquisition at a July 1 meeting. Bard, which specializes in vascular, urology, oncology and surgical technology, said SenoRX will operate within its peripheral vascular division. Murray Hill, N.J.-based Bard reported sales of $2.5 billion and net income of $461.4 million in 2009, its regulatory filings show. SenoRX reported revenue of $55.6 million and a net loss of $2.9 million in 2009, according to the regulatory filings.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.